Regeneron Pharmaceuticals, Inc. (REGN) KPIs and segments
Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Regeneron Pharmaceuticals · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Regeneron Pharmaceuticals: 46 chỉ số vận hành, trong đó có Dupixent (dupilumab, EYLEA HD & EYLEA Franchise (aflibercept và Libtayo (cemiplimab, lấy từ 186 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collaboration revenue($M) | 3,001 | 2,455 | 1,900 | 1,971 | 1,968 | 1,861 | 1,531 | 1,607 | 1,660 | 1,524 | 1,267 | 1,370 | |
Net product sales($M) | 1,805 | 1,642 | 1,535 | 1,675 | 1,588 | 1,631 | 1,416 | 2,003 | 1,946 | 1,919 | 1,761 | 1,852 | |
EYLEA1 | |||||||||||||
United States($M) | 400 | 412 | 473 | 577 | 681 | 754 | 736 | 1,190 | 1,145 | 1,231 | 1,202 | 1,338 | |
Libtayo($M)2 | 550 | 489 | 438 | 425 | 365 | 377 | 285 | 367 | 289 | 297 | 264 | 244 | |
United States($M) | 396 | 343 | 286 | 285 | 219 | 248 | 193 | 251 | 195 | 182 | 159 | 155 | |
Rest Of World($M) | 154 | 147 | 152 | 140 | 146 | 129 | 92.6 | 116 | 94.1 | 115 | 105 | 89 | |
Other revenue($M) | 310 | 193 | 171 | 239 | 198 | 184 | 81.9 | 179 | 114 | 105 | 117 | 213 | |
Inmazeb($M)2 | 35.6 | 0 | 1 | ||||||||||
United States($M) | 37.4 | 0 | 40.2 | 35.6 | 62.1 | ||||||||
Rest Of World($M) | 0 | 0 | 0 | 1 | |||||||||
Lynozyfic($M) | 19 | 16.5 | 11.2 | 0.80 | 0 | 0 | |||||||
Other products($M) | 0.80 | 0 | 31.3 | 10.1 | 0 | 0 | 0 | 0 | 0 | ||||
Evkeeza1 | |||||||||||||
United States($M) | 55.5 | 53.3 | 45.7 | 47.3 | 42.8 | 41.2 | 30.9 | 38.1 | 32.4 | 30.4 | 24.8 | 24 | |
Praluent1 | |||||||||||||
United States($M) | 81.5 | 74.7 | 66.6 | 72.2 | 67.7 | 65.8 | 56.8 | 62.7 | 52.9 | 56.1 | 70 | 61.3 | |
EYLEA HD1 | |||||||||||||
United States($M) | 699 | 596 | 468 | 431 | 393 | 307 | |||||||
EYLEA HD And EYLEA1 | |||||||||||||
United States($M) | 1,099 | 1,009 | 942 | 1,111 | 1,148 | 1,043 | |||||||
ELYEA HD And EYLEA1 | |||||||||||||
United States($M) | 1,083 | 1,111 | 1,148 | 1,043 | 1,495 | 1,537 | 1,535 | 1,402 | 1,461 | ||||
ELYEA HD1 | |||||||||||||
United States($M) | 506 | 431 | 393 | 307 | 305 | 392 | 304 | 200 | 123 | ||||
Dupixent (dupilumab — recorded by Sanofi) — Global Net Product Sales ($M)($M)3 | 6,541 | 5,998 | 4,880 | 4,940 | 4,857 | 4,345 | 3,666 | 3,698 | 3,817 | 3,556 | 3,077 | 3,216 | |
Dupixent (dupilumab — recorded by Sanofi) — U.S. Net Product Sales ($M)($M) | 5,064 | 4,561 | 3,558 | 3,734 | 3,619 | 3,205 | 2,629 | 2,746 | 2,825 | 2,610 | 2,218 | 2,486 | |
Dupixent (dupilumab — recorded by Sanofi) — Rest of World (ROW) Net Product Sales ($M)($M) | 1,476 | 1,437 | 1,322 | 1,206 | 1,238 | 1,140 | 1,036 | 952 | 993 | 946 | 859 | 730 | |
Dupixent (dupilumab — recorded by Sanofi) — Global Net Product Sales YoY Growth (%)(%) | 35.0% | 38.0% | 33.0% | 34.0% | 27.0% | 22.0% | 19.0% | 15.0% | 23.0% | 27.0% | 24.0% | 31.0% | |
EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Global Net Product Sales ($M)($M)4 | 1,741 | 1,675 | 1,670 | 1,900 | 1,965 | 2,125 | 1,901 | 2,383 | 2,469 | 2,443 | 2,251 | 2,350 | |
EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Rest of World (ROW) Net Product Sales ($M)($M) | 643 | 667 | 729 | 817 | 854 | 978 | 858 | 888 | 932 | 908 | 849 | 890 | |
EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Global Net Product Sales YoY Growth (%)(%) | -11.0% | -21.0% | -12.0% | -20.0% | -20.0% | -13.0% | -16.0% | 1.0% | 4.0% | 2.0% | -1.0% | 1.0% | |
EYLEA HD / EYLEA 8 mg (aflibercept 8 mg) — Global Net Product Sales ($M)($M)2 | 1,083 | 963 | 801 | 819 | 663 | 635 | 453 | 395 | 468 | 363 | 215 | 123 | |
EYLEA HD / EYLEA 8 mg (aflibercept 8 mg) — Rest of World (ROW) Net Product Sales ($M)($M) | 384 | 366 | 333 | 312 | 232 | 242 | 146 | 90.4 | 75.2 | 59.1 | 15.2 | ||
EYLEA HD / EYLEA 8 mg (aflibercept 8 mg) — Global Net Product Sales YoY Growth (%)(%) | 63.0% | 52.0% | 77.0% | 107.0% | 42.0% | 75.0% | 111.0% | ||||||
EYLEA (aflibercept 2 mg) — Global Net Product Sales ($M)($M)2 | 658 | 712 | 869 | 1,082 | 1,302 | 1,490 | 1,447 | 1,988 | 2,001 | 2,079 | 2,036 | 2,227 | |
EYLEA (aflibercept 2 mg) — Rest of World (ROW) Net Product Sales ($M)($M) | 259 | 300 | 396 | 505 | 621 | 736 | 711 | 798 | 857 | 849 | 834 | 890 | |
EYLEA (aflibercept 2 mg) — Global Net Product Sales YoY Growth (%)(%) | -49.0% | -52.0% | -40.0% | -46.0% | -35.0% | -28.0% | -29.0% | -5.0% | |||||
Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Global Net Product Sales ($M)($M)2 | 550 | 489 | 438 | 425 | 365 | 377 | 285 | 367 | 289 | 297 | 264 | 244 | |
Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Rest of World (ROW) Net Product Sales ($M)($M) | 154 | 147 | 152 | 140 | 146 | 129 | 92.6 | 116 | 94.1 | 115 | 105 | 89 | |
Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Global Net Product Sales YoY Growth (%)(%) | 51.0% | 30.0% | 54.0% | 16.0% | 27.0% | 27.0% | 8.0% | 50.0% | 24.0% | 42.0% | 45.0% | 44.0% | |
Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Global Net Product Sales ($M)($M)2 | 261 | 266 | 246 | 226 | 216 | 222 | 193 | 180 | 191 | 192 | 201 | 187 | |
Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Rest of World (ROW) Net Product Sales ($M)($M) | 179 | 191 | 179 | 154 | 148 | 156 | 137 | 118 | 139 | 136 | 131 | 126 | |
Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Global Net Product Sales YoY Growth (%)(%) | 21.0% | 20.0% | 27.0% | 25.0% | 13.0% | 16.0% | -4.0% | -4.0% | 16.0% | 37.0% | 38.0% | 40.0% | |
Kevzara (sarilumab — recorded by Sanofi) — Global Net Product Sales ($M)($M)3 | 256 | 206 | 145 | 152 | 154 | 152 | 116 | 135 | 120 | 110 | 94.1 | 112 | |
Kevzara (sarilumab — recorded by Sanofi) — U.S. Net Product Sales ($M)($M) | 193 | 143 | 101 | 100 | 103 | 95.7 | 72.8 | 82.4 | 72.7 | 65.1 | 50 | 66.2 | |
Kevzara (sarilumab — recorded by Sanofi) — Rest of World (ROW) Net Product Sales ($M)($M) | 62.9 | 62.5 | 44.3 | 52 | 51.1 | 56.5 | 43.6 | 52.4 | 47.4 | 44.6 | 44.1 | 46 | |
Kevzara (sarilumab — recorded by Sanofi) — Global Net Product Sales YoY Growth (%)(%) | 66.0% | 35.0% | 24.0% | 13.0% | 28.0% | 39.0% | 24.0% | 20.0% | 25.0% | 10.0% | 20.0% | 38.0% | |
Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — Global Net Product Sales ($M)($M)2 | 19 | 16.5 | 11.2 | 0.80 | |||||||||
Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — U.S. Net Product Sales ($M)($M) | 18.6 | 16.2 | 10.7 | 0.80 | |||||||||
Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — Rest of World (ROW) Net Product Sales ($M)($M) | 0.40 | 0.30 | 0.50 | ||||||||||
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Global Net Product Sales ($M)($M)4 | 91.3 | 84.6 | 106 | 125 | 71.1 | 72.1 | 54.6 | 103 | 92.6 | 52.8 | 44.2 | 105 | |
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — U.S. Net Product Sales ($M)($M) | 56.2 | 54 | 77.1 | 92.9 | 43.1 | 42.1 | 31.1 | 78.5 | 68.2 | 30.9 | 25.3 | 86.5 | |
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Rest of World (ROW) Net Product Sales ($M)($M) | 35.1 | 30.6 | 29.3 | 31.8 | 28 | 30 | 23.5 | 24.8 | 24.4 | 21.9 | 18.9 | 18.5 | |
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Global Net Product Sales YoY Growth (%)(%) | 28.0% | 17.0% | 95.0% | 21.0% | -22.0% | 37.0% | 24.0% | -2.0% | 135.0% | 31.0% | 24.0% | 232.0% | |
REGEN-COV / Ronapreve (casirivimab & imdevimab — U.S. by Regeneron, ROW by Roche) [legacy FY20–FY24] — Global Net Product Sales ($M)($M)2 | 1.20 | 1.10 | 1.20 | 5.60 | |||||||||
REGEN-COV / Ronapreve (casirivimab & imdevimab — U.S. by Regeneron, ROW by Roche) [legacy FY20–FY24] — Rest of World (ROW) Net Product Sales ($M)($M) | 1.20 | 1.10 | 1.20 | 5.60 | |||||||||
REGEN-COV / Ronapreve (casirivimab & imdevimab — U.S. by Regeneron, ROW by Roche) [legacy FY20–FY24] — Global Net Product Sales YoY Growth (%)(%) | -100.0% | -100.0% | -99.0% | ||||||||||
Total Consolidated Revenues Recorded by Regeneron ($M)($M)3 | 5,116 | 4,291 | 3,605 | 3,884 | 3,754 | 3,676 | 3,029 | 3,789 | 3,721 | 3,547 | 3,145 | 3,434 | |
Total Consolidated Revenues YoY Growth (%)(%) | 36.0% | 17.0% | 19.0% | 3.0% | 1.0% | 4.0% | -4.0% | 10.0% | 11.0% | 12.0% | -1.0% | 1.0% | |
Net Product Sales Recorded by Regeneron ($M)($M)5 | 1,805 | 1,642 | 1,535 | 1,675 | 1,588 | 1,631 | 1,416 | 2,003 | 1,946 | 1,919 | 1,761 | 1,852 | |
Net Product Sales Recorded by Regeneron YoY Growth (%)(%) | 14.0% | 1.0% | 8.0% | -16.0% | -18.0% | -15.0% | -20.0% | 8.0% | 9.0% | 8.0% | 6.0% | 9.0% | |
EYLEA HD & EYLEA Total — U.S. Net Product Sales ($M)($M)3 | 1,099 | 1,009 | 942 | 1,083 | 1,111 | 1,148 | 1,043 | 1,495 | 1,537 | 1,535 | 1,402 | 1,461 | |
EYLEA HD & EYLEA Total U.S. Net Product Sales YoY Growth (%)(%) | -1.0% | -12.0% | -10.0% | -28.0% | -28.0% | -25.0% | -26.0% | 2.0% | 3.0% | 2.0% | -2.0% | -2.0% | |
EYLEA HD — U.S. Net Product Sales ($M)($M)1 | 699 | 596 | 468 | 506 | 431 | 393 | 307 | 305 | 392 | 304 | 200 | 123 | |
EYLEA HD U.S. Net Product Sales YoY Growth (%)(%) | 62.0% | 52.0% | 52.0% | 66.0% | 10.0% | 29.0% | 54.0% | 148.0% | 166.0% | ||||
EYLEA (2 mg) — U.S. Net Product Sales ($M)($M)1 | 400 | 412 | 473 | 577 | 681 | 754 | 736 | 1,190 | 1,145 | 1,231 | 1,202 | 1,338 | |
EYLEA (2 mg) U.S. Net Product Sales YoY Growth (%)(%) | -41.0% | -45.0% | -36.0% | -52.0% | -41.0% | -39.0% | -39.0% | -11.0% | -21.0% | -18.0% | -16.0% | -11.0% | |
Libtayo — Global Net Product Sales Recorded by Regeneron ($M)($M)3 | 550 | 489 | 438 | 425 | 365 | 377 | 285 | 367 | 289 | 297 | 264 | 244 | |
Libtayo Global Net Product Sales YoY Growth (%)(%) | 51.0% | 30.0% | 54.0% | 16.0% | 26.0% | 27.0% | 8.0% | 50.0% | 25.0% | 41.0% | 49.0% | 61.0% | |
Libtayo — U.S. Net Product Sales Recorded by Regeneron ($M)($M)1 | 396 | 343 | 286 | 285 | 219 | 248 | 193 | 251 | 195 | 182 | 159 | 155 | |
Libtayo U.S. Net Product Sales YoY Growth (%)(%) | 81.0% | 38.0% | 49.0% | 14.0% | 12.0% | 36.0% | 21.0% | ||||||
Libtayo — Rest of World (ROW) Net Product Sales Recorded by Regeneron ($M)($M)1 | 154 | 147 | 152 | 140 | 146 | 129 | 92.6 | 116 | 94.1 | 115 | 105 | 89 | |
Libtayo ROW Net Product Sales YoY Growth (%)(%) | 5.0% | 13.0% | 63.0% | 21.0% | 55.0% | 12.0% | -11.0% | ||||||
Praluent — U.S. Net Product Sales Recorded by Regeneron ($M)($M)1 | 81.5 | 74.7 | 66.6 | 72.2 | 67.7 | 65.8 | 56.8 | 62.7 | 52.9 | 56.1 | 70 | 61.3 | |
Praluent U.S. Net Product Sales YoY Growth (%)(%) | 21.0% | 14.0% | 18.0% | 16.0% | 26.0% | 18.0% | -19.0% | 3.0% | 33.0% | 37.0% | 75.0% | 69.0% | |
Evkeeza — U.S. Net Product Sales Recorded by Regeneron ($M)($M)1 | 55.5 | 53.3 | 45.7 | 47.3 | 42.8 | 41.2 | 30.9 | 38.1 | 32.4 | 30.4 | 24.8 | 24 | |
Evkeeza U.S. Net Product Sales YoY Growth (%)(%) | 28.0% | 29.0% | 48.0% | 26.0% | 34.0% | 32.0% | 29.0% | 58.0% | 68.0% | 63.0% | 60.0% | 60.0% | |
Other Revenue (Royalties, BARDA Funding & Contract Manufacturing) ($M)($M)1 | 310 | 193 | 171 | 239 | 198 | 184 | 81.9 | 179 | 114 | 105 | 117 | 213 | |
Other Revenue YoY Growth (%)(%) | 57.0% | 5.0% | 109.0% | 33.0% | 74.0% | 77.0% | -30.0% | -16.0% | -17.0% | 51.0% | 1.0% | 66.0% | |
Total Collaboration Revenue (Sanofi, Bayer, Roche & Other) ($M)($M)3 | 3,001 | 2,455 | 1,900 | 1,971 | 1,968 | 1,861 | 1,531 | 1,607 | 1,660 | 1,524 | 1,267 | 1,370 | |
Sanofi Collaboration Revenue — Total ($M)($M)6 | 2,724 | 2,174 | 1,605 | 1,640 | 1,617 | 1,444 | 1,183 | 1,213 | 1,263 | 1,146 | 910 | 993 | |
Sanofi Collaboration Revenue YoY Growth (%)(%) | 68.0% | 51.0% | 36.0% | 35.0% | 28.0% | 26.0% | 30.0% | 22.0% | 19.0% | 21.0% | 14.0% | 19.0% | |
Regeneron's Net Share of Profits (Losses) from Commercialization of Antibodies (Dupixent, Praluent, Kevzara) ($M)($M)5 | 2,575 | 2,033 | 1,451 | 1,486 | 1,456 | 1,282 | 1,018 | 1,043 | 1,088 | 988 | 804 | 886 | |
Antibody Profit-Sharing Schedule — Dupixent & Kevzara Net Product Sales Recorded by Sanofi ($M)($M) | 6,796 | 6,204 | 5,025 | 5,092 | 5,011 | 4,497 | 3,782 | 3,832 | 3,937 | 3,666 | 3,171 | 3,328 | |
Antibody Profit-Sharing Schedule — Regeneron's Share of Collaboration Profits before Development Balance Reimbursement ($M)($M) | 2,575 | 2,286 | 1,728 | 1,771 | 1,724 | 1,497 | 1,180 | 1,189 | 1,263 | 1,149 | 926 | 1,032 | |
Antibody Profit-Sharing Schedule — Reimbursement of Development Balance to Sanofi (Deduction from Profit Share) ($M)($M) | -253 | -277 | -285 | -268 | -215 | -162 | -146 | -175 | -161 | -122 | -146 | ||
Antibody Profit-Sharing Schedule — Regeneron's Net Profit Share as % of Dupixent & Kevzara Net Product Sales (%)(%) | 38.0% | 33.0% | 29.0% | 29.0% | 29.0% | 27.0% | 28.0% | 27.0% | 25.0% | ||||
Sanofi Antibody Collaboration — Remaining Contingent Development Balance Payable by Regeneron ($M)($M) | 278 | 595 | 905 | 1,200 | 1,453 | 1,635 | 1,810 | 2,013 | 2,200 | 2,330 | |||
Sanofi Collaboration — Reimbursement for Manufacturing of Commercial Supplies ($M)($M) | 149 | 142 | 154 | 154 | 162 | 162 | 165 | 170 | 175 | 157 | 106 | 107 | |
Sanofi Collaboration — Net R&D Expense Reimbursement / (Obligation) ($M)($M) | -38.4 | -19.4 | -16.7 | -12.6 | -23.5 | -18 | -15.5 | -11.3 | -7.80 | -9.10 | -18.6 | -17 | |
Sanofi Collaboration — Reimbursement of Commercialization-Related (SG&A) Expenses ($M)($M) | 196 | 189 | 184 | 194 | 183 | 194 | 159 | 196 | 169 | 151 | 140 | 150 | |
Sanofi Collaboration — Net Accounts Receivable Due from Sanofi ($M)($M) | 2,840 | 2,272 | 1,713 | 1,611 | 1,494 | 1,337 | 1,193 | 1,216 | 1,271 | 1,133 | 947 | 1,029 | |
Bayer Collaboration Revenue — Total ($M)($M)5 | 267 | 276 | 287 | 319 | 345 | 415 | 344 | 377 | 391 | 375 | 356 | 377 | |
Bayer Collaboration Revenue YoY Growth (%)(%) | -23.0% | -33.0% | -17.0% | -15.0% | -12.0% | 11.0% | -3.0% | 4.0% | -1.0% | 6.0% | |||
Regeneron's Share of Net Profits from Ex-U.S. Commercialization of EYLEA 8 mg & EYLEA ($M)($M)4 | 212 | 227 | 240 | 270 | 312 | 383 | 317 | 349 | 368 | 353 | 334 | 345 | |
Bayer Profit-Sharing Schedule — Ex-U.S. EYLEA 8 mg & EYLEA Net Product Sales Recorded by Bayer ($M)($M) | 643 | 667 | 729 | 817 | 854 | 978 | 858 | 888 | 932 | 908 | 849 | 890 | |
Bayer Profit-Sharing Schedule — Regeneron's Share of Collaboration Profit before Bayer Development Reimbursement ($M)($M) | 226 | 242 | 255 | 286 | 328 | 400 | 334 | 366 | 384 | 369 | 351 | 361 | |
Bayer Profit-Sharing Schedule — Reimbursement of Development Expenses Incurred by Bayer ($M)($M) | -14.8 | -15.1 | -15.4 | -15.7 | -16.1 | -16.5 | -16.3 | -17.2 | -16.6 | -16 | -16.6 | -15.3 | |
Bayer Profit-Sharing Schedule — Regeneron's Net Profit Share as % of Ex-U.S. EYLEA Sales (%)(%) | 33.0% | 34.0% | 33.0% | 37.0% | 39.0% | 37.0% | 39.0% | 39.0% | 39.0% | ||||
Bayer Collaboration — Reimbursement for Manufacturing of Ex-U.S. Commercial Supplies ($M)($M) | 55.3 | 48.9 | 47.3 | 48.6 | 32.9 | 31.6 | 26.6 | 28.3 | 23.2 | 22.1 | 22.1 | 31.4 | |
Bayer Collaboration — Net R&D Expense Reimbursement / (Obligation) ($M)($M) | -0.30 | -0.60 | 1 | -1.10 | -3.90 | -5.60 | -9.40 | -13.3 | -11.8 | -14.7 | -8.70 | -8.90 | |
Bayer Collaboration — Net Accounts Receivable Due from Bayer ($M)($M) | 235 | 223 | 241 | 288 | 363 | 388 | 373 | 350 | 377 | 373 | 359 | 382 | |
Roche Collaboration Revenue (Ronapreve / REGEN-COV Ex-U.S. Gross Profit Share) [legacy FY21–FY24] ($M)($M) | 0 | 0.50 | 0.40 | 0.50 | 2.10 | ||||||||
Total Accounts Receivable, Net ($M)($M)3 | 7,579 | 6,565 | 5,731 | 5,741 | 5,687 | 5,610 | 5,561 | 6,212 | 6,107 | 5,717 | 5,222 | 5,667 | |
Trade Accounts Receivable, Net ($M)($M) | 4,132 | 3,784 | 3,529 | 3,458 | 3,471 | 3,581 | 3,760 | 4,278 | 4,142 | 3,958 | 3,739 | 3,888 | |
Customer Revenue Concentration — Besse Medical (Cencora) Share of Gross Product Revenue (%)(%) | 4,800.0% | 4,500.0% | 4,500.0% | 4,900.0% | 5,200.0% | 5,100.0% | 5,100.0% | 5,100.0% | 5,100.0% | ||||
Customer Revenue Concentration — McKesson Corporation Share of Gross Product Revenue (%)(%) | 3,000.0% | 3,200.0% | 3,000.0% | 3,000.0% | 2,400.0% | 2,500.0% | 2,400.0% | 2,400.0% | 2,400.0% | ||||
Total Research and Development (R&D) Expenses ($M)($M)4 | 1,795 | 1,632 | 1,544 | 1,626 | 1,475 | 1,422 | 1,327 | 1,412 | 1,272 | 1,200 | 1,248 | 1,177 | |
Direct Research and Development Expenses — Total ($M)($M)10 | 590 | 539 | 499 | 461 | 454 | 454 | 388 | 430 | 386 | 364 | 408 | 333 | |
Direct Clinical R&D — Dupixent (dupilumab) ($M)($M) | 28.8 | 24.3 | 29.3 | 30.1 | 27.6 | 28.1 | 25.5 | 32.4 | 31.3 | 28.8 | 36.3 | 36 | |
Direct Clinical R&D — Libtayo (cemiplimab) ($M)($M) | 13.4 | 15.7 | 19.7 | 18.8 | 18 | 18.5 | 20.8 | 18.4 | 17.9 | 20.2 | 22.6 | 23.1 | |
Direct Clinical R&D — Fianlimab (anti-LAG-3 antibody) ($M)($M) | 44.9 | 72.7 | 42.2 | 52.6 | 55.8 | 47.9 | 51.5 | 47.1 | 53.4 | 51 | 64 | 31.7 | |
Direct Clinical R&D — Lynozyfic (linvoseltamab, BCMAxCD3 bispecific) ($M)($M) | 64.2 | 63.9 | 73.8 | 47.9 | 32.8 | 53.6 | 31.7 | 30.1 | 25.4 | 23.1 | 63.3 | 14.4 | |
Direct Clinical R&D — Ordspono (odronextamab, CD20xCD3 bispecific) ($M)($M) | 57.9 | 49.3 | 48.6 | 46.3 | 50.1 | 42.8 | 26.2 | 35.3 | 33.8 | 34.3 | 26.1 | 29.7 | |
Direct Clinical R&D — Itepekimab (anti-IL-33 antibody) ($M)($M) | 33.8 | 23.6 | 21.8 | 20.9 | 28.1 | 34.5 | 28.3 | 28.4 | 24.2 | 24.2 | 19.3 | 16.2 | |
Direct Clinical R&D — Pozelimab & Cemdisiran (anti-C5 / C5 siRNA) ($M)($M) | 21.4 | 23.7 | 17.5 | 21.6 | 16.5 | 16.3 | 12.8 | 30.1 | 17.6 | 19.8 | 12 | 17.6 | |
Direct Clinical R&D — Trevogrumab (anti-GDF8 / myostatin antibody) ($M)($M) | 11.5 | 16.3 | 16.7 | 17.9 | 23.6 | 15.5 | 14.3 | 6.40 | 5.10 | 7.10 | |||
Direct Clinical R&D — EYLEA HD (aflibercept 8 mg) ($M)($M) | 16.5 | 21.1 | 22.6 | 30.3 | 22.3 | 28.9 | 25.1 | 21.9 | 24.3 | ||||
Direct R&D — Other Clinical Product Candidates & Earlier-Stage Research Programs ($M)($M) | 263 | 210 | 196 | 91 | 214 | 178 | 167 | 172 | 148 | 132 | 136 | 138 | |
Indirect Research and Development Expenses — Total ($M)($M)3 | 724 | 714 | 714 | 683 | 672 | 673 | 666 | 679 | 630 | 621 | 609 | 604 | |
Indirect R&D — Payroll and Benefits ($M)($M) | 472 | 460 | 484 | 461 | 438 | 449 | 452 | 433 | 408 | 423 | 419 | 406 | |
Indirect R&D — Lab Supplies and Other Research and Development Costs ($M)($M) | 76.3 | 71.5 | 59.3 | 65.8 | 67.5 | 64.9 | 60 | 66.1 | 63 | 56.5 | 55.9 | 52.7 | |
Indirect R&D — Occupancy and Other Operating Costs ($M)($M) | 176 | 182 | 171 | 156 | 166 | 159 | 154 | 180 | 159 | 142 | 135 | 145 | |
R&D — Clinical Manufacturing Costs ($M)($M) | 508 | 405 | 364 | 362 | 381 | 337 | 310 | 355 | 307 | 260 | 275 | 283 | |
R&D — Reimbursement of R&D Expenses by Collaborators (Deduction) ($M)($M) | -26.5 | -26.2 | -33.6 | -36 | -32.8 | -42.3 | -37.3 | -51.4 | -51 | -44.6 | -43.8 | -42.4 | |
Acquired In-Process Research and Development (IPR&D) Expense ($M)($M) | 21.5 | 127 | 102 | 18.7 | 83.1 | 10 | 12.3 | 13.8 | 56.2 | 23.9 | 7.10 | 30 | |
Non-GAAP Gross Margin on Net Product Sales (%)(%)3 | 86.0% | 87.0% | 86.0% | 85.0% | 86.0% | 86.0% | 85.0% | 86.0% | 89.0% | 89.0% | 89.0% | ||
GAAP Gross Margin on Net Product Sales (%)(%) | 82.0% | 78.0% | 76.0% | 81.0% | 82.0% | 83.0% | 81.0% | 84.0% | 87.0% | 87.0% | 86.0% | ||
Non-GAAP Cost of Goods Sold (COGS) ($M)($M)3 | 246 | 221 | 209 | 257 | 227 | 222 | 217 | 271 | 217 | 214 | 196 | 259 | |
GAAP Cost of Goods Sold (COGS) ($M)($M) | 322 | 361 | 373 | 319 | 281 | 276 | 266 | 327 | 262 | 258 | 240 | 307 | |
COGS Reconciling Item — Stock-Based Compensation Expense ($M)($M) | -28.9 | -26.7 | -33.1 | 25.1 | -19.9 | -20.9 | -19.5 | 26.6 | 18.3 | 18.2 | 20.9 | 25.1 | |
COGS Reconciling Item — Intangible Asset Amortization Expense ($M)($M) | -47.1 | -43.8 | -39.4 | 36.9 | -33.7 | -32.4 | -28.7 | 29.1 | 26.1 | 25.1 | 23.2 | 21.9 | |
GAAP Cost of Collaboration and Contract Manufacturing (COCM) ($M)($M)1 | 252 | 216 | 296 | 266 | 241 | 255 | 199 | 239 | 229 | 222 | 193 | 210 | |
Non-GAAP Cost of Collaboration and Contract Manufacturing (COCM) ($M)($M) | 252 | 216 | 281 | 241 | 255 | 199 | |||||||
Non-GAAP Research and Development (R&D) Expense ($M)($M)2 | 1,654 | 1,500 | 1,408 | 1,331 | 1,350 | 1,283 | 1,186 | 1,224 | 1,146 | 1,072 | 1,122 | 1,031 | |
GAAP Research and Development (R&D) Expense ($M)($M) | 1,795 | 1,632 | 1,544 | 1,626 | 1,475 | 1,422 | 1,327 | 1,412 | 1,272 | 1,200 | 1,248 | 1,177 | |
R&D Reconciling Item — Stock-Based Compensation Expense ($M)($M) | -140 | -131 | -135 | 140 | -125 | -139 | -141 | 175 | 124 | 122 | 123 | 133 | |
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)2 | 588 | 574 | 560 | 691 | 541 | 542 | 537 | 681 | 613 | 667 | 584 | 622 | |
GAAP Selling, General and Administrative (SG&A) Expense ($M)($M) | 678 | 662 | 648 | 775 | 658 | 634 | 633 | 792 | 714 | 759 | 689 | 738 | |
SG&A Reconciling Item — Stock-Based Compensation Expense ($M)($M) | -86.6 | -85.5 | -89.2 | 83.9 | -92 | -91.8 | -95.2 | 103 | 83.1 | 82.6 | 86.2 | 82.6 | |
Non-GAAP Other Income (Expense), Net ($M)($M)2 | 176 | 172 | 163 | 185 | 159 | 189 | 173 | 181 | 179 | 166 | 145 | 117 | |
GAAP Other Income (Expense), Net ($M)($M) | 236 | 234 | 188 | 164 | 737 | 439 | 313 | -32.1 | 314 | 559 | -50.7 | 175 | |
Other Income Reconciling Item — (Gains) Losses on Investments in Equity Securities [through Q1 2025] ($M)($M) | -140 | 213 | -135 | -393 | 196 | -58.1 | |||||||
Non-GAAP Net Income ($M)($M)5 | 2,150 | 1,543 | 1,040 | 1,249 | 1,287 | 1,424 | 928 | 1,390 | 1,462 | 1,351 | 1,116 | 1,366 | |
GAAP Net Income ($M)($M) | 1,949 | 1,297 | 727 | 845 | 1,460 | 1,392 | 809 | 918 | 1,341 | 1,432 | 722 | 1,160 | |
Total Pretax GAAP to Non-GAAP Reconciling Items ($M)($M) | 246 | 298 | 377 | 463 | -282 | 34.1 | 145 | 585 | 145 | -114 | 488 | 252 | |
Income Tax Effect of GAAP to Non-GAAP Reconciling Items ($M)($M) | -48.8 | -54.3 | -67.5 | -91.4 | 64.7 | -2.10 | -25.6 | -113 | -23.4 | 32.8 | -93.8 | -45.3 | |
Non-GAAP Effective Tax Rate (%)(%)1 | 15.0% | 15.5% | 13.9% | 17.1% | 13.1% | 8.3% | 11.6% | 9.9% | 10.7% | 10.8% | 6.1% | 2.4% | |
GAAP Effective Tax Rate (%)(%) | 14.7% | 15.1% | 12.5% | 19.1% | 17.2% | 8.4% | 10.6% | 4.2% | 10.2% | 12.0% | -3.0% | -1.0% | |
Non-GAAP Diluted Net Income Per Share ($/sh)($)3 | 20.07 | 14.29 | 9.47 | 11.44 | 11.83 | 12.89 | 8.22 | 12.07 | 12.46 | 11.56 | 9.55 | 11.86 | |
Non-GAAP Basic Net Income Per Share ($/sh)($) | 21.14 | 15.01 | 10 | 12.13 | 12.42 | 13.55 | 8.70 | 12.92 | 13.53 | 12.50 | 10.35 | 12.82 | |
Shares Used in Calculating Non-GAAP Diluted EPS (M shares) | 107.10 | 108.00 | 109.80 | 109.10 | 108.80 | 110.40 | 113.00 | 115.10 | 117.40 | 116.90 | 116.80 | 115.20 | |
Shares Used in Calculating Non-GAAP Basic EPS (M shares) | 101.70 | 102.80 | 104.00 | 102.90 | 103.60 | 105.10 | 106.70 | 107.60 | 108.10 | 108.10 | 107.80 | 106.60 | |
Free Cash Flow (Table 3 Non-GAAP Reconciliation) ($M)($M)2 | 1,483 | 573 | 848 | 922 | 1,417 | 925 | 816 | 1,063 | 1,049 | 174 | 1,379 | 838 | |
Net Cash Provided by Operating Activities ($M)($M) | 1,783 | 813 | 1,079 | 1,171 | 1,619 | 1,144 | 1,045 | 1,263 | 1,291 | 354 | 1,513 | 1,090 | |
Less: Capital Expenditures ($M)($M) | 300 | 240 | 231 | 249 | 201 | 219 | 229 | 200 | 242 | 181 | 134 | 251 | |
Inventories, Net ($M)($M)5 | 2,895 | 3,084 | 3,104 | 3,201 | 3,254 | 3,206 | 3,192 | 3,087 | 3,018 | 2,874 | 2,715 | 2,581 | |
Inventories — Raw Materials ($M)($M) | 548 | 611 | 631 | 642 | 710 | 752 | 839 | 880 | 857 | 844 | 815 | 789 | |
Inventories — Work in Process ($M)($M) | 1,345 | 1,511 | 1,525 | 1,642 | 1,566 | 1,545 | 1,470 | 1,342 | 1,230 | 1,155 | 1,108 | 1,122 | |
Inventories — Finished Goods ($M)($M) | 101 | 142 | 161 | 190 | 170 | 144 | 110 | 140 | 165 | 154 | 181 | 147 | |
Inventories — Other Inventories / Deferred Cost of Sales ($M)($M) | 901 | 821 | 788 | 728 | 809 | 764 | 774 | 726 | 767 | 721 | 612 | 522 | |
Inventory Valuation Reserves Balance [legacy through FY23] ($M)($M) | 706 | ||||||||||||
Property, Plant and Equipment, Net ($M)($M) | 5,728 | 5,459 | 5,266 | 5,120 | 5,002 | 4,841 | 4,694 | 4,600 | 4,439 | 4,306 | 4,226 | 4,146 | |
Intangible Assets, Net ($M)($M) | 1,316 | 1,310 | 1,287 | 1,257 | 1,381 | 1,352 | 1,167 | 1,149 | 1,120 | 1,102 | 1,059 | 1,039 | |
Long-Term Debt (Senior Notes due 2030 & 2050) ($M)($M)1 | 1,987 | 1,987 | 1,986 | 1,986 | 1,986 | 1,985 | 1,985 | 1,984 | 1,984 | 1,984 | 1,983 | 1,983 | |
Finance Lease Liabilities ($M)($M) | 0 | 0 | 0 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | |
Share Repurchases — Cash Paid for Common Stock Repurchases ($M)($M)5 | 400 | 1,169 | 794 | 672 | 664 | 1,062 | 1,041 | 973 | 735 | 604 | 291 | 289 | |
Share Repurchases — Value of Shares Repurchased ($M)($M) | 377 | 1,165 | 803 | 671 | 663 | 1,070 | 1,052 | 976 | 738 | 601 | 298 | 291 | |
Share Repurchases — Common Shares Repurchased (M shares) | 0.50 | 1.70 | 1.00 | 1.10 | 1.90 | 1.50 | 0.60 | 0.60 | 0.30 | ||||
Share Repurchase Program — Remaining Dollar Authorization Available ($M)($M) | 2,157 | 2,534 | 688 | 1,486 | 2,156 | 2,814 | 3,874 | 1,917 | 2,893 | 3,631 | 1,233 | 1,531 | |
Treasury Stock — Carrying Value on Balance Sheet ($M)($M)1 | 20,949 | 20,575 | 19,414 | 18,613 | 17,944 | 17,285 | 16,218 | 15,167 | 14,192 | 13,456 | 12,857 | 12,560 | |
Treasury Stock — Shares Held in Treasury (M shares) | 36.90 | 36.40 | 34.70 | 33.70 | 32.70 | 31.60 | 29.70 | 28.20 | 27.00 | 26.40 | 25.80 | 25.50 | |
Cash Dividends Declared Per Common Share (Initiated Q1 2025) ($/sh)($) | 0.94 | 0.94 | 0.94 | 0.88 | 0.88 | 0.88 | 0.88 | ||||||
Total Stock-Based Compensation Expense ($M)($M) | 256 | 243 | 257 | 249 | 237 | 252 | 256 | 304 | 225 | 223 | 230 | 240 | |
Income Tax Expense (Benefit) ($M)($M)1 | 335 | 231 | 104 | 199 | 303 | 127 | 96.3 | 40.4 | 152 | 196 | -21.3 | -12 | |
Deferred Tax Assets, Net on Balance Sheet ($M)($M) | 4,536 | 4,381 | 4,191 | 4,077 | 3,847 | 3,572 | 3,443 | 3,314 | 3,015 | 2,881 | 2,765 | 2,575 | |
Full-Time Employees — Global Total [annual] (employees)1 | |||||||||||||
Average Headcount Disclosed in MD&A Operating Expenses Discussion [through Q1 2026 / FY25] (employees) | 15,343 | 15,301 | 15,207 | 15,158 | 14,642 | 14,176 | 13,677 | ||||||
U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products — SAAR ($B) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
Income Statement — Total revenues ($M)($M)13 | 5,116 | 4,291 | 3,605 | 3,884 | 3,754 | 3,676 | 3,029 | 3,789 | 3,721 | 3,547 | 3,145 | 3,434 | |
Total operating expenses ($M)($M) | 3,068 | 2,997 | 2,963 | 3,004 | 2,728 | 2,596 | 2,437 | 2,799 | 2,541 | 2,478 | 2,394 | 2,461 | |
Research and development expense ($M)($M) | 1,795 | 1,632 | 1,544 | 1,626 | 1,475 | 1,422 | 1,327 | 1,412 | 1,272 | 1,200 | 1,248 | 1,177 | |
Selling, general, and administrative expense ($M)($M) | 678 | 662 | 648 | 775 | 658 | 634 | 633 | 792 | 714 | 759 | 689 | 738 | |
Income from operations ($M)($M) | 2,048 | 1,294 | 643 | 880 | 1,027 | 1,080 | 592 | 990 | 1,180 | 1,070 | 751 | 973 | |
Other income (expense), net ($M)($M) | 236 | 234 | 188 | 164 | 737 | 439 | 313 | -32.1 | 314 | 559 | -50.7 | 175 | |
Interest expense ($M)($M) | 10.6 | 11 | 12.9 | 12.2 | 19.3 | 3.60 | 8.70 | 10.5 | 13.8 | 14.8 | 16.1 | 18.3 | |
Income before income taxes ($M)($M) | 2,284 | 1,528 | 831 | 1,044 | 1,763 | 1,519 | 905 | 958 | 1,493 | 1,628 | 701 | 1,148 | |
Income tax expense ($M)($M) | 335 | 231 | 104 | 199 | 303 | 127 | 96.3 | 40.4 | 152 | 196 | -21.3 | -12 | |
Net income ($M)($M) | 1,949 | 1,297 | 727 | 845 | 1,460 | 1,392 | 809 | 918 | 1,341 | 1,432 | 722 | 1,160 | |
Net income per share — Basic ($/sh)($) | 19.16 | 12.62 | 6.99 | 14.09 | 13.24 | 7.58 | 12.40 | 13.25 | 6.70 | ||||
Net income per share — Diluted ($/sh)($) | 18.45 | 12.23 | 6.75 | 13.62 | 12.81 | 7.27 | 11.54 | 12.41 | 6.27 | ||||
Weighted-average basic shares outstanding (M) | 101.70 | 102.80 | 104.00 | 103.60 | 105.10 | 106.70 | 108.10 | 108.10 | 107.80 | ||||
Weighted-average diluted shares outstanding (M) | 105.60 | 106.00 | 107.70 | 107.20 | 108.60 | 111.20 | 116.20 | 115.40 | 115.10 | ||||
Balance Sheet — Total assets ($M)($M)15 | 44,405 | 41,731 | 40,869 | 40,559 | 40,169 | 38,219 | 37,545 | 37,759 | 37,442 | 36,087 | 34,370 | 33,080 | |
Cash and cash equivalents ($M)($M) | 3,659 | 2,456 | 2,963 | 3,118 | 2,506 | 1,996 | 3,090 | 2,489 | 2,012 | 1,921 | 2,602 | 2,730 | |
Marketable securities — current ($M)($M) | 5,642 | 5,539 | 5,791 | 5,487 | 5,937 | 5,474 | 5,259 | 6,524 | 7,785 | 7,888 | 7,918 | 8,115 | |
Accounts receivable, net ($M)($M) | 7,579 | 6,565 | 5,731 | 5,741 | 5,687 | 5,610 | 5,561 | 6,212 | 6,107 | 5,717 | 5,222 | 5,667 | |
Inventories ($M)($M) | 2,895 | 3,084 | 3,104 | 3,201 | 3,254 | 3,206 | 3,192 | 3,087 | 3,018 | 2,874 | 2,715 | 2,581 | |
Total current assets ($M)($M) | 20,795 | 18,446 | 18,209 | 18,022 | 17,981 | 16,860 | 17,572 | 18,661 | 19,334 | 19,082 | 18,872 | 19,479 | |
Marketable securities — noncurrent ($M)($M) | 9,557 | 9,828 | 9,786 | 10,261 | 10,286 | 10,058 | 9,276 | 8,900 | 8,491 | 7,722 | 6,979 | 5,397 | |
Property, plant, and equipment, net ($M)($M) | 5,728 | 5,459 | 5,266 | 5,120 | 5,002 | 4,841 | 4,694 | 4,600 | 4,439 | 4,306 | 4,226 | 4,146 | |
Intangible assets, net ($M)($M) | 1,316 | 1,310 | 1,287 | 1,257 | 1,381 | 1,352 | 1,167 | 1,149 | 1,120 | 1,102 | 1,059 | 1,039 | |
Deferred tax assets ($M)($M) | 4,536 | 4,381 | 4,191 | 4,077 | 3,847 | 3,572 | 3,443 | 3,314 | 3,015 | 2,881 | 2,765 | 2,575 | |
Accounts payable ($M)($M) | 1,140 | 1,159 | 1,027 | 939 | 904 | 724 | 706 | 790 | 497 | 562 | 671 | 607 | |
Total current liabilities ($M)($M) | 6,202 | 5,531 | 5,108 | 4,368 | 4,425 | 3,667 | 3,567 | 3,944 | 3,661 | 3,509 | 3,581 | 3,423 | |
Long-term debt ($M)($M) | 1,987 | 1,987 | 1,986 | 1,986 | 1,986 | 1,985 | 1,985 | 1,984 | 1,984 | 1,984 | 1,983 | 1,983 | |
Total liabilities ($M)($M) | 10,907 | 10,019 | 9,445 | 9,302 | 9,212 | 8,280 | 8,158 | 8,406 | 8,116 | 7,881 | 7,379 | 7,107 | |
Retained earnings ($M)($M) | 39,472 | 37,621 | 36,424 | 35,797 | 35,046 | 33,680 | 32,384 | 31,673 | 30,755 | 29,415 | 27,982 | 27,260 | |
Total stockholders' equity ($M)($M) | 33,499 | 31,711 | 31,424 | 31,257 | 30,958 | 29,939 | 29,388 | 29,354 | 29,326 | 28,206 | 26,991 | 25,973 | |
Cash Flow Statement — Operating cash flow ($M)($M)6 | 1,783 | 813 | 1,079 | 1,171 | 1,619 | 1,144 | 1,045 | 1,263 | 1,291 | 354 | 1,513 | 1,090 | |
Depreciation and amortization ($M)($M) | 121 | 124 | 123 | 145 | 137 | 135 | 127 | 126 | 122 | 121 | 114 | 113 | |
Stock-based compensation ($M)($M) | 256 | 243 | 257 | 249 | 237 | 252 | 256 | 304 | 225 | 223 | 230 | 240 | |
Capital expenditures ($M)($M) | 300 | 240 | 231 | 249 | 201 | 219 | 229 | 200 | 242 | 181 | 134 | 251 | |
Investing cash flow ($M)($M) | -288 | -92.7 | -429 | 220 | -403 | -1,094 | 648 | 351 | -574 | -557 | -1,687 | -66.2 | |
Financing cash flow ($M)($M) | -290 | -1,225 | -802 | -780 | -718 | -1,128 | -1,089 | -1,136 | -634 | -478 | 47.1 | -446 | |
Repurchases of common stock ($M)($M) | 400 | 1,169 | 794 | 672 | 664 | 1,062 | 1,041 | 973 | 735 | 604 | 291 | 289 | |
20 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Regeneron Pharmaceuticals, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026; Q3 2026 ended September 30, 2026). Regeneron manages its business as a single global biopharmaceutical operating segment (Note 16), so operational performance is tracked through two distinct commercial lenses: (1) Global Net Product Sales of Regeneron-Discovered Products across U.S. and Rest of World (Table 5 — whether recorded by Regeneron or by collaboration partners Sanofi, Bayer, and Roche) and (2) Regeneron-Recorded Consolidated Revenues, Collaboration Profit-Sharing Schedules (Table 4), and Direct R&D Spend by Clinical Program.
- Core commercial, collaboration & R&D KPIs (Groups 1–6) cover: (1) Global Net Product Sales of Regeneron-Discovered Products (Table 5: Dupixent $4,860.8M in Q3 2026 / $17,774.4M in FY25, +26% in FY25; EYLEA HD & EYLEA Franchise $1,908.7M in Q3 2026 / $8,303.6M in FY25 across EYLEA HD $661.7M and EYLEA $1,247.0M in Q3 2026; Libtayo $448.6M in Q3 2026 / $1,447.6M in FY25; Praluent $201.9M in Q3 2026 / $807.7M in FY25; Kevzara $156.9M in Q3 2026 / $596.3M in FY25; Lynozyfic $35.0M in Q3 2026; and Other Products $58.0M in Q3 2026 / $241.7M in FY25, plus legacy REGEN-COV, ARCALYST, and ZALTRAP); (2) Regeneron-Recorded Consolidated Revenues ($3,754.2M in Q3 2026 / $14,342.8M in FY25: Net Product Sales $2,299.1M in Q3 2026 / $8,522.4M in FY25, Collaboration Revenue $1,394.7M in Q3 2026 / $5,376.4M in FY25, and Other Revenue $60.4M in Q3 2026 / $444.0M in FY25); (3) Sanofi & Bayer Collaboration Revenue (Table 4) and Profit-Sharing Schedules (Sanofi Antibody Profit Share $1,517.8M in Q3 2026 / $5,263.5M in FY25, 31% of partner sales in Q3 2026 after development balance was fully reimbursed in Q2 2026; Bayer Ex-U.S. EYLEA Profit Share $328.9M in Q3 2026 / $1,439.8M in FY25, 37% of $893.4M ex-U.S. sales in Q3 2026); (4) Gross-to-Net (GTN) Sales Deductions Reserve Rollforward ($1,806.4M ending balance, $7,328.9M provisions, and $7,007.8M payments/credits in FY25 across Rebates/Chargebacks/Discounts, Distribution Fees, and Other Deductions) and Specialty Distributor Concentration (Besse Medical / Cencora 48% and McKesson 30% of gross product revenue in Q3 2026; 91% of trade AR at FY25); (5) R&D Expenses ($1,468.2M in Q3 2026 / $5,738.3M in FY25: Direct R&D $703.2M in Q3 2026 / $2,824.2M in FY25 disaggregated across Lynozyfic, Ordspono, Fianlimab, Itepekimab, Dupixent, Libtayo, Pozelimab, Trevogrumab, EYLEA HD, and Other Candidates; Indirect R&D $471.3M in Q3 2026; Clinical Manufacturing $328.7M in Q3 2026; and Collaborator Reimbursements -$35.0M in Q3 2026), Acquired IPR&D ($199.1M in Q3 2026), and Science/Pipeline KPIs (13 approved medicines, ~40 clinical candidates, >2.5M human exomes sequenced by Regeneron Genetics Center); and (6) GAAP vs. Non-GAAP Reconciliations & Free Cash Flow (Table 3: 84.0% Non-GAAP / 81.2% GAAP Gross Margin on Net Product Sales, $1,226.4M Non-GAAP Net Income, $11.42 Non-GAAP Diluted EPS, and $1,073.8M Free Cash Flow in Q3 2026).
- Groups 7–9 cover: (7) Manufacturing Inventories by Stage ($3,477.1M net at Q3 2026: Raw Materials $727.4M, WIP $2,021.1M, Finished Goods $644.6M, Deferred Cost of Sales $84.0M), Bioreactor Cell Culture Capacity (160,000 liters in Rensselaer NY and 150,000 liters in Limerick Ireland in FY25), Facility Space (2.11M sq ft in Tarrytown NY, 2.75M sq ft in Rensselaer NY, and 818,700 sq ft in Limerick Ireland in FY25), PP&E by Category ($5,112.1M net at Q3 2026), and Intangible Assets ($914.3M net at Q3 2026 with 5-year estimated amortization schedule); (8) Senior Notes Debt ($1,986.2M at Q3 2026), Finance & Operating Leases, Capital Return ($651.2M share repurchases / 0.89M shares in Q3 2026; $1,588.8M remaining buyback authorization; $0.94/share quarterly dividend declared in Q3 2026), Stock-Based Compensation ($280.1M in Q3 2026 / $1,069.9M in FY25), and Income Taxes (DTA breakdown $4,193.5M net at Q3 2026 and UTB rollforward $878.8M at FY25); and (9) Global Workforce (15,172 full-time employees at FY25: 13,221 U.S., 1,622 Ireland, 329 Other International; 7,448 IOPS manufacturing, 3,275 Research & Preclinical, 2,265 Clinical & Regulatory), Diversity & Turnover (87% engagement, 7.6% total turnover, 51.0% women globally, 41.2% POC in U.S. at FY24), CEO Pay Ratio (35:1 / $189,031 median employee compensation in FY25), Workplace Safety (0.61 TRIR / 0.30 LTIR / 0 fatalities in FY24), STEM & Community Investment (1,452,469 students supported with a STEM experience and $461.4M in-kind donations in FY24), and Environmental Sustainability (Scope 1, 2 & 3 GHG emissions, electricity, renewable energy, water & waste).
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-11-04.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Global, U.S. & Rest of World Net Product Sales of Regeneron-Discovered Medicines (Table 5 — Regeneron, Sanofi, Bayer & Roche)
- Dupixent (dupilumab — recorded by Sanofi) — Global Net Product Sales ($M) ($M)36 kỳ
- EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Global Net Product Sales ($M) ($M)36 kỳ
- Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Global Net Product Sales ($M) ($M)32 kỳ
- Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Global Net Product Sales ($M) ($M)36 kỳ
- Kevzara (sarilumab — recorded by Sanofi) — Global Net Product Sales ($M) ($M)36 kỳ
- Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — Global Net Product Sales ($M) ($M)4 kỳ
- Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Global Net Product Sales ($M) ($M)23 kỳ
Regeneron-Recorded Consolidated Revenues, Net Product Sales by Brand & Revenue Streams
Sanofi, Bayer & Roche Collaboration Revenue Breakdown & Profit-Sharing Schedules (Table 4 & Note 3)
Gross-to-Net (GTN) Sales Deductions Reserve Rollforward, Trade Receivables & Distributor Concentration
- Gross-to-Net (GTN) Sales Deductions Reserve — Ending Balance [annual] ($M) ($M)14 kỳ
- Gross-to-Net (GTN) Sales Deductions — Total Provisions Recorded [annual] ($M) ($M)11 kỳ
- Gross-to-Net (GTN) Sales Deductions — Total Credits & Payments Utilized [annual] ($M) ($M)13 kỳ
- Total Accounts Receivable, Net ($M) ($M)67 kỳ
R&D Expenses by Clinical Program & Cost Category, Acquired IPR&D & Science/Pipeline Metrics
GAAP to Non-GAAP Reconciliations, Product Gross Margin, Effective Tax Rate & Free Cash Flow (Table 3)
- Non-GAAP Gross Margin on Net Product Sales (%) (%)11 kỳ
- Non-GAAP Research and Development (R&D) Expense ($M) ($M)31 kỳ
- Non-GAAP Selling, General and Administrative (SG&A) Expense ($M) ($M)31 kỳ
- Non-GAAP Other Income (Expense), Net ($M) ($M)30 kỳ
- Non-GAAP Net Income ($M) ($M)36 kỳ
- Free Cash Flow (Table 3 Non-GAAP Reconciliation) ($M) ($M)28 kỳ
Manufacturing Inventories by Stage, Bioreactor Cell Culture Capacity, Facility Space, PP&E & Intangibles
- Inventories, Net ($M) ($M)60 kỳ
- Bioreactor Cell Culture Manufacturing Capacity — Rensselaer, New York IOPS Facility [annual] (liters)11 kỳ
- Facility Space — Tarrytown, New York R&D & Corporate Headquarters Campus [annual] (sq ft)11 kỳ
- Property, Plant and Equipment, Net ($M) ($M)67 kỳ
- Intangible Assets, Net ($M) ($M)18 kỳ
Senior Notes Debt, Leases, Capital Return (Share Repurchases & Dividends), Stock-Based Compensation & Income Taxes
Global Workforce by Geography & Department, Diversity, CEO Pay Ratio, Safety, STEM Community & Environment (ESG)
- Full-Time Employees — Global Total [annual] (employees)11 kỳ
- Employee Engagement Rate [annual] (%) (%)7 kỳ
- CEO Pay Ratio (X:1) [annual]7 kỳ
- Occupational Health & Safety — Total Recordable Incident Rate (TRIR per 100 FTE) [annual]6 kỳ
- Community & STEM Impact — Students Supported with a STEM Experience [annual] (students)5 kỳ
- Greenhouse Gas (GHG) Emissions — Total Scope 1, 2 & 3 Footprint [annual] (metric tons CO2e)7 kỳ
- Energy — Total Electricity Consumption [annual] (kWh)7 kỳ
- Waste & Water — Total Waste Generated [annual] (metric tons)7 kỳ
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)
- PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100)129 kỳ
- CPI: Medical Care Commodities in U.S. City Average (Index 1982-84=100)128 kỳ
- U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products — SAAR ($B)43 kỳ
- Income Statement — Total revenues ($M) ($M)70 kỳ
- Balance Sheet — Total assets ($M) ($M)67 kỳ
- Cash Flow Statement — Operating cash flow ($M) ($M)69 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Regeneron Pharmaceuticals
- Form 10-Q (filed 2026-10-30) ↗
- Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
- Form 8-K (exhibit991q42025.htm, filed 2026-01-30) ↗
- Form 10-K (filed 2026-02-04) ↗
- Form 10-K (regn-20251231.htm, filed 2026-02-04) ↗
- 2024 Regeneron Responsibility Report ↗
- Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
- Form 8-K (exhibit991q32026.htm; 0000872589-26-000023|exhibit991q22026.htm, filed 2026-10-30) ↗
- Proxy Statement (DEF 14A) (regn-20260424.htm, filed 2026-04-24) ↗
- FRED (PCU325412325412) ↗
- FRED (CUSR0000SAM1) ↗
- FRED (MRTSSM44611USS) ↗
See a number that looks wrong?